New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Alzamend Neuro, Inc. (ALZN) vs Cardio Diagnostics Holdings, Inc. (CDIO)

Alzamend Neuro, Inc. and Cardio Diagnostics Holdings, Inc. are both Biotechnology companies. Alzamend Neuro, Inc. and Cardio Diagnostics Holdings, Inc. are of similar size ($4.9M and $4.9M). Alzamend Neuro, Inc. has the higher net margin (0.00% vs −42,401.3%) and the higher return on invested capital (0.00% vs −228.0%). Across the 13 metrics below, Alzamend Neuro, Inc. leads on 7 and Cardio Diagnostics Holdings, Inc. on 6.

Valuation

Metric ALZN CDIO Biotechnology median
P/E n/m n/m 8.26
P/S n/m 319.11 9.20
P/B 0.79 0.85 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 0.30 n/m 0.67
EV/Sales n/m 61.40 9.05
Earnings yield (225.49%) (153.33%) (34.24%)
Free cash flow yield (156.37%) (118.47%) (24.77%)

Profitability

Metric ALZN CDIO Biotechnology median
Gross margin 0.00% 100.00% 70.18%
Operating margin 0.00% (42,328.76%) 0.00%
Net margin 0.00% (42,401.31%) 0.00%
Free cash flow margin 0.00% (37,804.58%) 0.00%
Return on equity (163.23%) (93.55%) (51.58%)
Return on assets (122.36%) (87.24%) (45.91%)
Return on invested capital 0.00% (227.99%) 0.00%

Growth

Metric ALZN CDIO Biotechnology median
Revenue growth (TTM) — (3.16%) 7.20%
EPS growth (last fiscal year) 76.77% 60.15% 29.04%
Revenue growth, 5-year CAGR — — 9.48%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ALZN CDIO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 17.44 4.83
Net debt to EBITDA 0.08 0.84 1.01

Dividend

Metric ALZN CDIO Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric ALZN CDIO Biotechnology median
Market cap 4.92m 4.88m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack